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Abstract: Background: Protein Z is a glycoprotein that acts as a co-factor for the inhibition of activated coagulation factor 
X. Protein Z circulating in abnormal levels has been associated with increased risk for acute ischemic events. Non-arteritic 
Anterior Ischemic Optic Neuropathy (N-AION) is caused by acute ischemic infarction of the optic nerve head, supplied 
by the posterior ciliary arteries. 
Objectives: The aim was to investigate whether there is an association between N-AION and plasma protein Z levels. 
Patients and Methods: Twenty-six cases of confirmed N-AION and fifty-two controls were included in the study group. 
Protein Z was estimated in thawed citrate plasma on both N-AION cases and controls by an enzyme immunoassay. The 
imprecision of the estimation was satisfactory (CV = 4, 6%). 
Results: The controls’ protein Z values distributed within a range 340 to 4200 ng/ml (median = 1420, mean = 1673, SD = 
1040 ng/ml). Patients’ protein Z values distributed within a range 420 to 3600 ng/ml (median = 1030, mean = 1520, SD = 
939 ng/ml). There was no statistical difference between the two distributions (Independent t-test, p=0.529). 
Conclusion: In our study, protein Z levels are not implicated in the pathogenesis of non-arteritic anterior ischemic optic 
neuropathy (N-AION). 
Keywords: Protein Z, Non-arteritic anterior ischemic optic neuropathy. 
INTRODUCTION 
  Protein Z (PZ) is a single chain, vitamin K- dependent 
glycoprotein that was purified from human plasma in 1984 
[1, 2]. 
  The amino acid sequence of PZ shows a wide homology 
with many vitamin K-dependent coagulation factors, such as 
factors VII, IX, X and anticoagulant protein C, but the 
protein does not act as expected for a zymogen form of a 
coagulation factor. PZ does not serve a proteolytic action 
because it lacks the proper amino acids residues of a serine 
protease on the active center [3, 4]. A cofactor role, in the 
inhibition of activated coagulation factor X (f Xa), 
dependent on phospholipids and calcium ions, was 
recognized for PZ in 1998 [5].
  The inhibitory function is 
exerted by the Protein Z- dependent protease inhibitor (ZPI), 
which circulates in the human plasma in a complex with PZ 
[6].
 The cofactor action of PZ is manifested after its binding 
to phospholipids and presumably involves the proper 
localization of ZPI-PZ complex on the phospholipid surface, 
for interaction with the fXa [5, 7]. 
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  In experimental animal models [8]
  and in humans [9] 
several studies have suggested that low plasma PZ levels 
might contribute to venous or arterial thrombosis. 
  In cases of venous thrombosis a potential association 
with low PZ levels was only demonstrated in subgroups of 
patients (men and individuals older than 55 years) but no 
effect of a concomitant factor V Leiden (FVL) genotype was 
detected [10, 11]. 
  A number of clinical studies which explore the role of PZ 
on coronary heart disease [12], ischemic stroke [11] and 
deep vein thrombosis [13] patients have been published. 
Particularly in ischemic stroke, patients or at least subgroups 
of patients [11] with low levels [14, 15]
 or high levels [16-
18] of PZ have been associated with increased risk of stroke. 
On the other hand, there are studies that claim no association 
between PZ levels and the risk for stroke [19]. 
  Although an absolute comparison of these studies is 
impossible, since a lot of differences exist between them, the 
opposing results that are presented are scientifically 
intriguing. 
  Anterior ischemic optic neuropathy (AION) is caused by 
acute ischemic infarction of the optic nerve head, which is 
supplied by the posterior ciliary arteries [20, 21]. There are 
two different types of AION. The most frequent   
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Non-arteritic anterior ischemic optic neuroparhy (N-AION) 
and arteritic anterior ischemic optic neuropathy (A-AION) 
usually associated with giant cell arteritis. 
  N-AION is the most common acute optic neuropathy in 
older age groups and may result in severe visual acuity or 
visual field loss [22].
 It is characterized by sudden, usually 
painless visual loss, relative afferent pupillary defect and 
optic disk edema [23]. Optic nerve atrophy-generalized or 
sectorial- ensues within the next few weeks. 
  Arteriosclerosis, hypertension [24] diabetes mellitus, 
ischemic heart disease, hypercholesterolemia [20], 
“crowded” optic disk [25], nocturnal hypotension [26] and 
sleep apnea syndrome [23]
  have been implicated as risk 
factors. 
  To our knowledge, there are extremely limited data, on 
the role of protein Z in ophthalmic disease. The aim of this 
study was to investigate whether alterations in protein Z 
might contribute to the enhanced risk of Non-arteritic 
anterior ischemic optic neuropathy. 
MATERIALS AND METHODOLOGY 
Study Design: Diagnostic and Exclusion Criteria 
  Diagnostic criteria for N-AION patients were as follows: 
sudden loss of vision, relative afferent pupillary defect, and 
visual field defects consistent with ischemic optic 
neuropathy and pale swollen optic disk. To exclude giant cell 
arteritis, a detailed history concerning the systematic 
symptoms of giant cell arteritis was aqcuired and C- reactive 
protein (CRP) levels and erythrocyte sedimentation rate 
(ESR) were measured. ESR over 35mm/h and CRP levels 
above 5 mg/L were considered suspicious for A-AION and 
those patients were excluded. In addition, biopsy of temporal 
arteries, if necessary, was performed. The same criteria along 
with raised white blood cells (WBC) from the blood count, 
served to exclude inflammatory conditions in both patients 
and controls. Other exclusion criteria were liver disease, 
myeloproliferative disorders and use of anticoagulants and 
contraceptives. In all patients MRI was performed to exclude 
demyelinization and intracranial tumors. All the patients are 
under systematic follow–up in regular intervals in our Eye 
Clinic. 
Laboratory Investigation 
  Blood samples from patients and controls were collected, 
approximately 2-3 days after original diagnosis, in sodium 
citrate and EDTA acid anticoagulants. A sample of citrated 
plasma from each patient was deep frozen for the 
determination of PZ. 
  A complete blood cell count, ESR and CRP were 
performed in all N-AION patients in a regular basis, using 
routine laboratory techniques [27]. 
  Search for the thrombophilic polymorphisms for factor V 
Leiden polymorphism (G1691A) and for prothrombin gene 
polymorphism G20210A, were done by polymerase chain 
reaction amplification and restriction enzyme digestion. 
  Detection of factor V Leiden mutation: In brief, a 267-
basepair (bp) segment of the factor V gene was amplified 
using specific primers (5'-TGC CCA GTG CTT AAC AAG  
 
ACC A-3' and 5'-TGT TAT CAC ACT GGT GCT AA-3'), as 
previously described [28]. The PCR product (10 mL) was 
digested with 4 U of DNA restriction enzyme Mnl I (New 
England Biolabs, Beverly, MA, USA), at 37°C for 16 h, 
subjected to 2% low melting point agarose (Sigma, MO, USA) 
gel electrophoresis and viewed under ultraviolet light after 
staining the gel with ethidium bromide. The digested amplicon 
from wild-type DNA gives 3 bands of 163, 67 and 37 bp, 
respectively; in contrast, heterozygous and homozygous FVL 
mutations show four (200, 163, 67 and 37 bp) and two (200 
and 67 bp) bands, respectively. Detection of prothrombin gene 
mutation:  For detection of G20210 prothrombin gene 
mutation, we used a PCR-RFLP method that has been 
described previously [29]. In brief, a 345-bp genomic DNA 
fragment encompassing a part of the prothrombin gene that 
contains the mutation was amplified by PCR using specific 
primers (5'-TCT AGA AAC AGT TGC CTG GC-3' and 5'-
ATA GCA CTG GGA GCA TTG AAG C-3'). The PCR 
product (10 mL) was digested with 20 U of Hind III (New 
England Biolabs, Beverly, MA, USA), at 37°C for 16 h, 
subjected to 3% low melting point agarose gel electrophoresis 
and read using ultraviolet light. Using this method, the wild-
type DNA yields a solitary 345-bp band, heterozygous 
G20210A mutation yields two bands of 345 and 322 bp, 
respectively and homozygous mutation only one band of 322 
bp. 
    The plasma PZ concentration was determined by a 
commercial enzyme immunoassay (Asserachrom Protein Z, 
Diagnostica Stago, France). This assay utilizes the 
quantitative sandwich enzyme immunoassay technique. 
Briefly, the standards and samples were incubated in 
duplicate wells of microtiter plate precoated with a 
monoclonal antibody specific for protein Z. Following 
incubation, repeated washings were performed to remove 
unbound materials and a second monoclonal antibody 
coupled with peroxidase directed against another epitope of 
protein Z was added to the assay plates. This step was 
followed by additional washes and an equal amount of 
stabilized chromogen; ortho-phenylenediamine (OPD) and 
urea peroxide substrate were added to each well. This 
initiates the development of color, which is halted at a set 
time by the addition of an acid solution. Optical densities 
were determined using a programmable micro plate reader 
(Bio-Tek Instruments, Winooski, Vermont, USA). Protein Z 
concentrations in the samples were determined by 
interpolation from individual standard curves. Since the 
sample size of our study is small, to minimize the inter-assay 
variation, we determined the protein Z values in one 
experiment, the same day by the same batch of reagents. One 
sample of thawed citrate plasma was examined in duplicate, 
for each patient or control. Protein Z values were calculated 
from a standard curve provided by the kit and expressed in 
ng/ml of plasma. The inter-assay variation calculated from 
the values of normal plasma was satisfactory (CV= 4.6 %) 
We considered protein Z deficiency levels <1000ngr/ml [14]. 
  Statistical Analysis was performed with Statistical 
Package for Social Sciences (SPSS version 14.0) using 
parametric (t-test) and non-parametric (Fisher’s exact test) 
statistic procedures where necessary. P-values less than 0.05 
were considered statistically significant. 
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RESULTS 
  According to diagnostic criteria, three patients with 
possible giant-cell arteritis were not included in the study. 
One more patient with meningioma was also excluded from 
the study. 
  Twenty-six patients with definite diagnosis of N-AION 
and in accordance with the criteria described were included 
in the study. Those were eighteen males and eight females 
with a mean age of 65 years (range 47 to 83). 
  The control group consisted of fifty-two healthy 
individuals from the same geographic area who were 
referred to the University Eye Clinic for cataract operation 
and had no history of N-AION, retinal artery or vein 
occlusion. The control group consisted of thirty males and 
twenty-two females with a mean age of 70 years (range 47 to 
85). 
  All patients and controls were free from autoimmune 
diseases, they were not taking anticoagulants and they had 
no other clinical or laboratory indication that they were 
under an acute inflammatory phase. In both groups WBC, 
ESR and CRP values were in the normal range. 
  Risk factors for atherosclerosis such as hyperlipidemia, 
(The United States NCEP guidelines for the diagnosis and 
treatment of hypercholesterolemia) diabetes mellitus, 
(Report of the Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus) hypertension, (2003 new 
European Society of Hypertension (ESH)/European Society 
of Cardiology (ESC) guidelines for the management of 
arterial hypertension ), defined according to strict criteria, 
were present in both groups with nearly the same incidence 
(Table 1). 
Table 1.  Incidence of Vascular Risk Factors 
 
Risk Factors  N-AION 
 (n =26) 
Controls  
(n =52) 
P-Value 
Diabetes melitus  5(19%)  11(21%)  0,84 
Hyperlipidemia 9(35%)  11(21%)  0,20 
Hypertension 9(35%)  16(31%)  0,73 
Ischemic heart disease  4(15%)  9(17%)  0,83 
 
   The concentration values of plasma PZ for the control 
group were distributed in a range from 340 to 4200 ng/ml 
with a mean of 1673 ng/ml (median 1420 ng/ml) and a SD of 
1040 ng/ml. 
  In N-AION patients the values of plasma PZ were also 
distributed in a range from 420 to 3600 ng/ml with a mean of 
1520 ng/ml (median 1030 ng/ml) and a SD 931 ng/ml (Fig. 
1). There was not any statistically significant difference 
between the PZ values of N-AION patients and the controls 
(Independent t-test, p=0.529). 
  There was not any statistical difference in PZ levels 
between males and females in each individual subgroup of 
N-AION patients and controls (P=0.37 and P=0.55 
respectively). 
  There was no statistically significant difference (P=0.18 
using the Kruscal-Wallis test) between the protein Z levels in 
groups of N-AION patients that had the attack in the left eye, 
in the right eye or in both eyes. 
  There was not any statistical difference using the Fisher’s 
exact test concerning factor V Leiden polymorphism 
(G1691A) (p=0.26) and prothrombin gene polymorphism 
G20210A (p=1) between patients and controls. 
   In two patients and one control subject that were carriers 
of factor V Leiden polymorphism, the values of protein Z 
were 1020, 1040 and 960 ng/ml, respectively. 
  Finally, all patients and controls were negative for lupus 
anticoagulant. 
DISCUSSION 
  N-AION is the most common acute optic neuropathy in 
older age groups which can affect both eyes in up to 40% of 
the patients [30]. 
  Recurrent attacks in the same eye, although uncommon, 
may also occur [31, 32]. The subsequent visual acuity or 
visual field loss may be devastating and can lead to serious 
visual impairment. More than half of the patients discover 
visual loss upon first awakening or when they first use 
vision, critically in the morning [23, 26].
 This was also the 
case in our study, where 17 (65%) of the patients realized the 
loss immediately after awakening. The prognosis of N-AION 
is poor due to optic nerve atrophy ensuing within the next 2-
4 weeks, and only a small number of the patients can show 
significant improvement. 
  The question whether there is an association between N-
AION and thrombophilic risk factors- inherited or acquired- 
provides quite controversial results. Salomon et al. found no 
association between N-AION and thrombophilic risk factors 
[20]. On the other hand, Nagy et al. [21]
  suggested that 
hyperfibrinogenemia and factor V Leiden may contribute to 
the pathogenesis of N-AION, while Van Cott et al. [33] 
recommend that testing for homocysteine and prothrombin 
G20210A mutation should be considered in these patients. 
J.F. Acheson and M.D. Sanders describe seven cases in 
which there is an associated thrombophilic state and non-
arteritic anterior ischemic optic neuropathy [34]. 
  N-AION is a multifactorial disease in which 
cerebrovascular risk factors such as diabetes mellitus, 
hypertension, hypercholesterolemia and ischemic heart 
disease may play an important role. However, because 
vascular risk factors are more common in individuals of 
similar age as patients with N-AION, the design of studies of 
this kind is very difficult to address the issue of whether 
these systemic factors represent true risk factors for the 
pathogenesis of N-AION, as Jakobson et al. refer to in their 
study [35]. 
  This is the first study, to our knowledge, to investigate 
whether there is an association between N-AION and plasma 
protein Z levels. The only study concerning PZ in 
ophthalmic disease, and specifically
  central retinal vein or 
artery occlusion, was held by Koren-Michowitz et al. [36]. 
  Although protein Z was characterized already in the 
1980s, its role in normal and pathologic coagulation is still 
controversial. There are studies suggesting an association 
between low plasma PZ levels and acute coronary 
syndromes [12, 13],
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demise and intrauterine growth restriction) [37, 38], and 
ischemic colitis [39]. 
  Opposing results and conclusions, concerning the 
association of ischemic stroke and PZ plasma concentrations 
have been reported. The behavior of PZ during the acute 
phase is also a matter of disagreement [13, 18]. 
  PZ concentration has a broad range in healthy individuals 
when samples of EDTA or citrate plasma are examined with 
immunofluoresence [2] or immunoenzymatic techniques [10], 
respectively. A lot of opposing results also exist, concerning 
the PZ values on patients with the same disease. Since the 
inter-assay variation reported for citrate plasma and 
immunoenzymatic techniques determination is near to 11% 
[15, 40], a part of this observed variability may be attributed to 
the unavoidable imprecision of the assays. We were able to 
minimize this inter-assay variation since we performed only 
one assay under very low variation (CV=4.6%). 
  On the other hand the accuracy of determination seems 
questionable since an International standard for PZ is lacking 
and as a consequence some researchers report their PZ 
results as percentages (%) of the mean, probably for 
comparison reasons [10, 11]. 
  Our results showed no statistically significant difference 
concerning PZ levels between the N-AION patients and 
controls. In consistency with this observation are the 
findings of Lopaciuk et al. 2002 [19] that the values of 
protein Z are not associated with the risk for stroke in young 
survivors and the observations of Refaai et al. 2006 [11]
 who 
did not find any association of PZ values and risk for stroke 
or coronary heart disease in older patients. 
  Contrary to our conclusions, due to small number of 
patients that we examined, there is always the possibility that 
some N-AION patients would have lower concentration 
values of PZ than the controls at the time of the attack. This 
would be observed in a minority of future patients, probably 
in less than 5%, according to our results. A none statistically 
significant trend for an increase of the levels of PZ as the 
time passed after the eye attack, that we observed, may 
support this, otherwise, small possibility. In contrast to this 
hypothesis and in analogy with our results, Refaai et al. 2006 
[11] found that PZ levels were not associated with the time 
of development of coronary heart disease or stroke. 
CONCLUSION 
  In conclusion, we compared a group of carefully selected 
N-AION patients, without inflammation, with a control 
group and we did not found a statistically significant 
difference (p=0.529) between the levels of protein Z. 
ABBREVIATIONS 
AION  =  Anterior ischemic optic neuropathy 
FVL  =  Concomitant factor V Leiden 
f Xa  =  Activated coagulation factor X 
N-AION  =  Non-arteritic Anterior Ischemic Optic  
     Neuropathy 
PZ =  Protein  Z 
ZPI  =  Protein Z- dependent protease inhibitor 
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